



Bloom Burton Award Gala

PROGRAM

2

WELCOME LETTER

Brian Bloom and Jolyon Burton

Clarissa Desjardins | 2018 Bloom Burton Award Winner

6

MESSAGE FROM THE PRIME MINISTER

Justin Trudeau

8

MESSAGE FROM THE PREMIER

Doug Ford

10

MESSAGE FROM THE MAYOR

John Tory

12

FINALIST PROFILES

Gilbert Godin and Greg Gubitz

David Lickrish

Poul Sorensen

22

JUDGING PANEL

Michael Altman

Dennis Purcell

Karen Bernstein

Melinda Richter

Cecilia Gonzalo

Mayukh Sukhatme

Carl Gordon

Contents

Thank you for attending the 2019 Bloom Burton Award Gala.

We are delighted that you are here to celebrate leaders in the Canadian healthcare sector.

The Bloom Burton Award seeks to honour an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker - anyone - who has made the greatest impact in Canada's innovative healthcare industry. It's time to celebrate those who advance medical science, attract and provide risk capital, launch new products and companies on the world stage or announce significant monetization events.

We received many nominations for this Award from the public-at-large and our international judging panel has narrowed and selected three finalists who deserve our recognition: Gilbert Godin and Gregory Gubitz of HLS Therapeutics Inc., David Lickrish of Highland Therapeutics Inc. and Poul Sorensen of the BC Cancer Agency and the University of British Columbia.

Let us raise our glasses and toast to their remarkable achievements!

A handwritten signature in black ink, appearing to read 'B. Bloom', with a long horizontal line extending to the right.

Brian Bloom

A handwritten signature in black ink, appearing to read 'Jolyon Burton', with a long horizontal line extending to the right.

Jolyon Burton

6:00PM

COCKTAIL RECEPTION

Pre-function Space and Outer Foyer

7:00PM

DINNER

Aria Ballroom

7:15PM

AWARD PROGRAM BEGINS

WELCOME REMARKS

Brian Bloom & Jolyon Burton

CELEBRATING GILBERT GODIN & GREG GUBITZ

Gilbert Godin and Greg Gubitz | HLS Therapeutics Inc.

CELEBRATING DAVID LICKRISH

David Lickrish | Highland Therapeutics Inc.

CELEBRATING POUL SORENSEN

Poul Sorensen | BC Cancer Agency and University of
British Columbia

WINNER ANNOUNCED

Clarissa Desjardins | 2018 Bloom Burton Award Winner

9:15PM

NETWORKING

Pre-function Space and Outer Foyer

Agenda

It is a pleasure to recognize this year's finalists for the Bloom Burton Award and their contributions to global healthcare and to the Canadian economy. To all the finalists, I extend my heartfelt congratulations to you, your teams and your families. The distinguished panel of judges has deemed your contributions to the Canadian innovative healthcare space to be the greatest among your peers for 2018! This is certainly something of which you can all be very proud.

I would like to thank Jolyon and Brian for the creation of this award. Only in its third year, it shines a light on our growing industry and celebrates the leaders who make it happen; advancing health through the creation of new knowledge, companies, products and services leading ultimately to the creation of wealth for all Canadians. The award also serves to highlight what happens between early academic discoveries and new drugs delivered to patients. The long, expensive and risky process of drug approval is often misunderstood by the public, contributing to the current focus on controlling drug costs and rationing healthcare. Importantly, the award brings us together in a well-deserved celebration of our efforts and in particular, in a recognition of the accomplishments of the nominees. This appropriate pause from our busy schedules gives us an opportunity to appreciate how far we have come as an industry and still how much further we must go.

WELCOME

Clarissa Desjardins

2018 Bloom Burton
Award Winner

“Health is the crown
on the healthy man’s
head that only the
sick man can see.”

- Robin Sharma

“Health is the crown on the healthy
man’s head that only the sick man can
see.” - Robin Sharma

To work in a field whose purpose is to
restore health for the sick is both an
immense privilege and responsibility.
As leaders, we have a responsibility to
the patients, employees and shareholders



we serve. It's been my experience that if you take care of the first two, the third takes care of itself. The reputation of our industry rests on our choices and behaviors. We have the privilege to contribute directly or indirectly to the alleviation of suffering from disease. This opportunity will endure until all diseases are treated or prevented and we can all wear the crown as we look forward to full and healthy lives.

I wish you all a wonderful evening, much health and congratulations to each of the nominees and ultimate winner for your outstanding achievements!

Clarissa Desjardins

2018 Bloom Burton Award Winner

Welcome



The Rt. Hon. Justin P.J. Trudeau, P.C., M.P.
Prime Minister of Canada



PRIME MINISTER • PREMIER MINISTRE

September 26, 2019

Dear Friends:

I am pleased to extend my warmest greetings to everyone attending the 2019 Bloom Burton Award Gala.

The Bloom Burton Award honours outstanding individuals who have made significant contributions to the Canadian healthcare sector. I join everyone in attendance this evening in congratulating this year's finalists: Mr. Gilbert Godin; Mr. Greg Gubitz; Mr. David Lickrish; and Professor Poul Sorensen. Their accomplishments make them most deserving of this special recognition.

I would also like to thank the organizers of tonight's gala for fostering innovation in the healthcare industry.

On behalf of the Government of Canada, I offer you my best wishes for an enjoyable evening and continued success.

Sincerely,

A handwritten signature in black ink, appearing to read 'Justin Trudeau', with a large, stylized initial 'J'.

The Rt. Hon. Justin P. J. Trudeau, P.C., M.P.
Prime Minister of Canada



Doug Ford
Premier of the Province of Ontario



Premier of Ontario - Premier ministre de l'Ontario

September 26, 2019

A MESSAGE FROM PREMIER DOUG FORD

I'm pleased to extend greetings to everyone taking part in the annual Bloom Burton Award Gala, held in honour of the scientists, inventors, executives, entrepreneurs, industry leaders, and policy-makers who have made significant contributions to Canada's healthcare industry.

Ontario's life sciences, biotechnology and other allied industries are vital aspects of our health care sector. We are fortunate to have a strong workforce and some of the best minds in the scientific field working in this great province.

I applaud the people at Bloom Burton & Co. for organizing this terrific event, and want to thank everyone who helped to make it a success. You can all be proud of your dedication to promoting and celebrating excellence in the Canadian health care industry. I also want to recognize all those being honoured this evening. Congratulations on your significant contributions. I wish you continued success.

Our government's goal to build a modern, integrated and sustainable health care system that puts the patient at the centre of care. As we continue to implement our modernization plan, our government will focus our investments where they will have the most impact — on frontline services that directly support patient care. By working together, we will build an integrated and patient-centred health care system.

Best wishes for a memorable evening.

A handwritten signature in blue ink, reading 'Doug Ford'.

Doug Ford
Premier



John Tory
Mayor of Toronto



Message from the Mayor

It is my pleasure to extend greetings and a warm welcome to everyone attending the Bloom Burton Award Gala.

Congratulations to this year's award recipients: visionary innovators who have made significant contributions to the Canadian healthcare sector.

The City of Toronto is proud of organizations and individuals that are committed to making a difference and recognizes their contributions to the economic and social well-being of our communities. Their tremendous efforts and talents impact the lives of many and make our city better.

On behalf of Toronto City Council, I thank the organizers and wish everyone an informative and enjoyable event.

Yours truly,



John Tory
Mayor of Toronto



“

This year's
finalists
represent the
best facets of
meaningful
and lasting
healthcare
innovation...

Jolyon Burton

Co-founder and President
Bloom Burton & Co.

GILBERT GODIN

HLS Therapeutics Inc.

Co-founder , President and
Chief Operations Officer

GREG GUBITZ

HLS Therapeutics Inc.

Co-founder and Chief
Executive Officer

DAVID LICKRISH

Highland Therapeutics Inc.

President and Chief Executive Officer

POUL SORENSEN

BC Cancer Agency

Distinguished Scientist

University of British Columbia

Professor, Dept. of Pathology and Laboratory Medicine

Finalists

Mr. Gilbert Godin's career in healthcare and life sciences spans across more than 3 decades in a variety of leadership and operational roles in North America and Europe.

FINALIST

Gilbert Godin

HLS Therapeutics Inc.

Mr. Godin is a co-founder and the President and Chief Operating Officer of HLS Therapeutics Inc. (TSX:HLS), a Canadian-based, North American-focused specialty pharmaceutical company. Prior to co-founding HLS, Mr. Godin was CEO of Duchesnay USA where he created the team that brought Duchesnay's first product to the US OBGYN market. Before that, Mr. Godin was Executive Vice President and Chief Operating Officer of Biovail Corporation; formerly Canada's largest publicly traded pharmaceutical company. In that capacity, he oversaw Business Operations, R&D, Plant Operations, Regulatory Affairs, and Licensing until the merger of Biovail and Valeant Pharmaceutical International Inc. (TSX:VRX) at the end of 2010. Prior to Biovail, Mr. Godin spent 7 years at MDS Pharma Services, leading a team of 4,000 scientists in 42 countries as President of the global Contractual Research Organization for the pharmaceutical market. Before joining MDS Pharma, Mr. Godin held Executive roles at Schering Plough in Canada and in Europe (France) where he directed the strategic and commercial deployment in the field of viral hepatitis, and at L'Oréal Healthcare in commercial and technical leadership roles.

Mr. Godin attended Sherbrooke University where he received a Bachelor in Mechanical Engineering in 1982 and the John Molson School of Business where he received a Master of Business Administration in 1992.



Co-founder, President and Chief Operations Officer

HLS Therapeutics Inc.



Co-founder and Chief Executive Officer

Mr. Gregory Gubitz is a seasoned life science executive and business lawyer, with significant transaction, investment and operating experience.

FINALIST

Greg Gubitz

HLS Therapeutics Inc.

Mr. Gubitz is a co-founder and the Chief Executive Officer of HLS Therapeutics Inc. (TSX:HLS), a Canadian-based, North American-focused specialty pharmaceutical company. Mr. Gubitz was Senior Vice President, Corporate Development and General Counsel of Biovail Corporation; formerly Canada's largest publicly traded pharmaceutical company. In that capacity he was responsible for mergers & acquisitions and product acquisitions, culminating with the \$7 billion merger of Biovail and Valeant Pharmaceutical International Inc. (TSX:VRX). Prior to joining Biovail, for 10 years he was a senior executive with MDS Capital, a leading North American venture capital company, focused on healthcare. As Chief Operating Officer of MDS Capital, Mr. Gubitz was responsible for all operational aspects of the company with a total of \$1 billion under management. Before joining MDS Capital, Mr. Gubitz was a partner at one of Canada's leading international law firms, where he represented numerous public and private companies in a wide range of financings, mergers & acquisitions, joint ventures, and business transactions.

Mr. Gubitz attended McGill University where he received a Bachelor of Arts Degree in 1979 and a Bachelor of Laws Degree in 1982. He was called to the Bar in the Province of Ontario in 1984.

David Lickrish is the Founder, Chief Executive Officer and Chairman of Highland Therapeutics Inc. and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics.

FINALIST

David Lickrish

Highland Therapeutics Inc.

Prior to founding Highland Therapeutics, David worked in Finance as a Senior Equity Research Analyst covering the Global Pharmaceutical Industry where he became familiar with Attention Deficit Hyperactivity Disorder (ADHD) and the unmet clinical needs associated with it such as early morning functioning (EMF). David recognized EMF as a significant challenge in the treatment of ADHD and used the knowledge garnered throughout his career to pursue potential solutions. Transitioning from the world of finance to healthcare, David dedicated himself to the creation of a patented, oral, once-daily drug-delivery technology now known as DELEXIS®. This novel technology was designed to enable the administration of medicines in the evening with the objective of achieving a therapeutic effect early the next morning and lasting throughout the day. Under his leadership, Ironshore has grown from a start-up research and development organization to an international pharmaceutical company with a proprietary drug-delivery technology and multiple late-stage drugs under development. Ironshore recently launched FDA-approved JORNAY PMTM indicated for the treatment of ADHD in patients 6 years and older in the United States.

JORNAY PM is the first and only ADHD stimulant that is dosed in the evening and is working when patients wake up, and lasts throughout the day and into the evening.

David studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. David has been a CFA Charter holder since 2001 and is the named inventor on more than 15 patents in the United States, Europe and Asia.

Highland Therapeutics Inc.



President and Chief Executive Officer



Distinguished Scientist and Professor

Dr. Poul Sorensen is a board certified anatomic pathologist, specializing in the molecular pathology of pediatric cancers.

He undertook his undergraduate, medical, and PhD degrees at the University of British Columbia (UBC) and McGill University, Montreal. He completed postdoctoral training at the University of Minnesota, Minneapolis and Children's Hospital Los Angeles, University of Southern California, after his Pathology training. He then returned to Vancouver to start his own laboratory at Children's and Women's Hospital in Vancouver.

Dr. Sorensen holds the Asa and Kashmir Johal Endowed Chair in Childhood Cancer Research, and he is a Professor of Pathology and Laboratory Medicine at UBC. Dr. Sorensen's research laboratory is located in the Department of Molecular Oncology at the BC Cancer Research Centre, where he is a distinguished scientist. His research focuses on targeting aberrant signaling pathways that are activated in childhood cancers and breast carcinoma.

Dr. Sorensen's laboratory uses a combination of genetic and biochemical approaches to identify proteins that are specifically altered in human tumours. His laboratory has discovered many novel genetic alterations in childhood cancer and breast tumours, and these discoveries have been translated into new diagnostic tests for specific tumours, and have advanced our understanding of how the involved proteins transmit signals that cause cells to become cancerous. Such information then allows for the rapid implementation of strategies to target these proteins therapeutically. Dr. Sorensen is also the Chair of the Translational Research Committee of the Children's Oncology Group (COG), the largest pediatric oncology clinical trials network in the world.

FINALIST

Poul Sorensen

BC Cancer Agency and
University of British
Columbia

Judging Panel

23

MICHAEL ALTMAN

Managing Director | Perceptive Advisors

24

KAREN BERNSTEIN

Co-founder and Chairman | BioCentury Inc.

25

CECILIA GONZALO

Partner | Oberland Capital

26

CARL GORDON

Partner and Co-Head of Global Private
Equity | OrbiMed Advisors

27

DENNIS PURCELL

Founder and Senior Advisor | Aisling Capital

28

MELINDA RICHTER

Global Head | Johnson & Johnson Innovation, JLABS

29

MAYUKH SUKHATME

President | Roivant Sciences

JUDGE

Michael Altman

Perceptive Advisors



Michael Altman joined Perceptive in 2007 and is a managing director on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO of ARYA Sciences Acquisition Corp. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Lyra Therapeutics and Vitruvius Therapeutics.

JUDGE

Karen Bernstein

BioCentury Inc.



Karen is co-founder and chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain, and at Achaogen Inc., which is developing drugs to treat multi-drug resistant gram-negative infections. She is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.

JUDGE

Cecilia Gonzalo

Oberland Capital



Cecilia Gonzalo is a Partner at Oberland Capital.

Prior to joining Oberland, she was a Managing Director at Vatera Healthcare Partners where she focused on venture capital and private equity investments in the biopharmaceutical industry. Previously, Ms. Gonzalo was a Managing Director with Essex Woodlands, a healthcare-focused growth equity firm. Ms. Gonzalo previously worked for 12 years in the healthcare group of Warburg Pincus LLC, a global private equity firm. Prior to her tenure at Warburg Pincus, Ms. Gonzalo worked at Goldman, Sachs & Co as an Analyst in the firm's Investment Banking Division and Principal Investment Area. Ms. Gonzalo currently serves as a board member and Co-President of the Harvard Business School Healthcare Alumni Association.

Ms. Gonzalo earned an A.B. in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School.

JUDGE

Carl Gordon

OrbiMed Advisors



Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last five years (2014 to 2018) Forbes® Magazine named Mr. Gordon one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).

JUDGE

Dennis Purcell

Aisling Capital



Dennis Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over \$10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.

Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.



JUDGE

Melinda Richter

Johnson & Johnson, JLABS

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson's sectors: consumer, medical device and pharmaceuticals.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS' operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA).



JUDGE

Mayukh Sukhatme

Roivant Sciences

Mayukh Sukhatme serves as President of Roivant Pharma, a business unit of Roivan Sciences. Roivant Pharma is focused on end-to-end biopharmaceutical company creation, launch, and oversight. Roivant Pharma companies include Myovant, Axovant, Arbutus, Urovant, Enzyvant, Dermavant, Genevant, Metavant, Immunovant, Respivant, Altavant, and Aruvant. Dr. Sukhatme joined Roivant in 2015 and previously served as Chief Business Officer.

From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned an M.D. from Harvard Medical School and a B.S. in Biology and a B.S. in Literature from MIT.

TABLE SPONSORS



**Baker
McKenzie.**



ESSA

BLOCK TICKET SPONSORS



J.P.Morgan



Sponsors

A large, semi-transparent number '2020' is centered over a dark blue background. The background features a blurred image of a large audience of people in business attire, seated at tables with glasses, suggesting a formal conference or networking event.

**BLOOM BURTON & CO.
HEALTHCARE INVESTOR
CONFERENCE**

2020

APRIL 20 - 21, 2020

METRO TORONTO CONVENTION CENTRE

TORONTO, ONTARIO

Bloom Burton
Award Gala

SEPTEMBER 26, 2019 | TORONTO
FOUR SEASONS HOTEL